Atlas Trials

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Clinical trial NCT02253316 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02253316
Sponsor
Washington University School of Medicine
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2015-01-20
Primary completion
2020-02-05
Enrollment
236

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.